Kiora Pharmaceuticals, Inc. Common Stock

KPRX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

12M

Short interest (May 15)

0.5%

Net Short (Jun 03 ): -0.1%

Borrow Fee

1.66%

↓ 17.9%

Available Shares

600K

↑ 6.9%

Price Chart

Company Overview

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001372514

Asset Type: CS

Market Data

Market Cap: $12,054,876

Employees: 13

Status: Active

Short Interest

Current Borrow Fee 1.66%

Range: 1.62% - 1.66%

Available Shares 600K

Range: 450K - 550K

Recent Changes

Fee Change: ↑ 1.0%

Available Change: ↓ 4.4%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime